194 related articles for article (PubMed ID: 15340764)
1. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
[TBL] [Abstract][Full Text] [Related]
2. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.
Wikstrand CJ; Cole VR; Crotty LE; Sampson JH; Bigner DD
Cancer Immunol Immunother; 2002 Feb; 50(12):639-52. PubMed ID: 11862416
[TBL] [Abstract][Full Text] [Related]
3. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.
Agarwalla P; Barnard Z; Fecci P; Dranoff G; Curry WT
J Immunother; 2012 Jun; 35(5):385-9. PubMed ID: 22576343
[TBL] [Abstract][Full Text] [Related]
4. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
5. Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model.
Clavreul A; Delhaye M; Jadaud E; Menei P
J Neurooncol; 2006 Aug; 79(1):9-17. PubMed ID: 16575532
[TBL] [Abstract][Full Text] [Related]
6. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
Morgan RA; Johnson LA; Davis JL; Zheng Z; Woolard KD; Reap EA; Feldman SA; Chinnasamy N; Kuan CT; Song H; Zhang W; Fine HA; Rosenberg SA
Hum Gene Ther; 2012 Oct; 23(10):1043-53. PubMed ID: 22780919
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
Sampson JH; Archer GE; Mitchell DA; Heimberger AB; Bigner DD
Semin Immunol; 2008 Oct; 20(5):267-75. PubMed ID: 18539480
[TBL] [Abstract][Full Text] [Related]
10. B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity.
Paul DB; Barth RF; Yang W; Shen GH; Kim J; Triozzi PL
Gene Ther; 2000 Jun; 7(12):993-9. PubMed ID: 10871746
[TBL] [Abstract][Full Text] [Related]
11. T9 glioma cells expressing membrane-macrophage colony stimulating factor produce CD4+ T cell-associated protective immunity against T9 intracranial gliomas and systemic immunity against different syngeneic gliomas.
Sanchez R; Williams C; Daza JL; Dan Q; Xu Q; Chen Y; Delgado C; Arpajirakul N; Jeffes EW; Kim RC; Douglass T; Al Atar U; Terry Wepsic H; Jadus MR
Cell Immunol; 2002 Jan; 215(1):1-11. PubMed ID: 12142031
[TBL] [Abstract][Full Text] [Related]
12. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas.
Wu AH; Xiao J; Anker L; Hall WA; Gregerson DS; Cavenee WK; Chen W; Low WC
J Neurooncol; 2006 Jan; 76(1):23-30. PubMed ID: 16155724
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors.
Gong H; Kovar JL; Cheung L; Rosenthal EL; Olive DM
Cancer Biol Ther; 2014 Feb; 15(2):185-93. PubMed ID: 24100437
[TBL] [Abstract][Full Text] [Related]
14. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4.
Yang W; Barth RF; Wu G; Ciesielski MJ; Fenstermaker RA; Moffat BA; Ross BD; Wikstrand CJ
Clin Cancer Res; 2005 Jan; 11(1):341-50. PubMed ID: 15671565
[TBL] [Abstract][Full Text] [Related]
15. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
[TBL] [Abstract][Full Text] [Related]
16. Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats.
Chen JC; Chen Y; Wu JM; Su YH; Tai KF; Tseng SH
Cancer Immunol Immunother; 2006 Jul; 55(7):873-83. PubMed ID: 16133106
[TBL] [Abstract][Full Text] [Related]
17. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
[TBL] [Abstract][Full Text] [Related]
18. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic.
Ciesielski MJ; Ahluwalia MS; Munich SA; Orton M; Barone T; Chanan-Khan A; Fenstermaker RA
Cancer Immunol Immunother; 2010 Aug; 59(8):1211-21. PubMed ID: 20422411
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.
Heimberger AB; Archer GE; Crotty LE; McLendon RE; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Neurosurgery; 2002 Jan; 50(1):158-64; discussion 164-6. PubMed ID: 11844246
[TBL] [Abstract][Full Text] [Related]
20. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
Choi BD; Kuan CT; Cai M; Archer GE; Mitchell DA; Gedeon PC; Sanchez-Perez L; Pastan I; Bigner DD; Sampson JH
Proc Natl Acad Sci U S A; 2013 Jan; 110(1):270-5. PubMed ID: 23248284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
